• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mannatech Reports Financial Results for Fourth Quarter and Year Ended 2025

    4/17/26 5:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email

    FLOWER MOUND, Texas, April 17, 2026 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter and year ended 2025.

    Fourth Quarter Results

    Fourth quarter net sales for 2025 were $26.6 million, a decrease of $2.4 million, or 8.2%, as compared to $29.0 million in the fourth quarter of 2024. During the fourth quarter, the Company's net sales declined 7.6% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.2 million in net sales as compared to the fourth quarter of 2024.

    Gross profit as a percentage of net sales decreased to 75.3% for the three months ended December 31, 2025, as compared to 80.5% for the same period in 2024.

    For the three months ended December 31, 2025, overall selling and administrative expenses decreased by $0.6 million to $9.8 million, as compared to $10.4 million for the same period in 2024. The decrease in selling and administrative expenses consisted primarily of a $0.2 million decrease in legal and consulting fees, a $0.1 million decrease in travel and entertainment costs, a $0.1 million decrease in bad debt, a $0.1 million decrease in miscellaneous administrative expenses and a $0.1 million decrease in warehouse costs.

    Fourth quarter operating loss for 2025 was $0.2 million as compared to operating income of $0.9 million for the fourth quarter of 2024.

    Fourth quarter net loss was $11.3 million, or $5.94 per diluted share, for the fourth quarter 2025, as compared to net income of $2.3 million, or $1.20 per diluted share, for the fourth quarter 2024. The higher net income in 2024 was a result of foreign currency exchange gains.

    Year End Results

    Net sales for 2025 were $108.0 million, a decrease of $9.9 million, or 8.3%, as compared to $117.9 million in 2024. Foreign currency exchange rate fluctuations had an overall unfavorable impact on 2025 net sales, reducing revenue by approximately $1.9 million compared to the prior year. On a Constant dollar basis (a Non-GAAP financial measure), net sales declined 6.8% in 2025 as compared to 2024. A significant portion of the revenue decline-approximately 15% of the total decrease in North America-was attributable to the implementation of a new ordering system, which negatively impacted sales.

    Gross profit as a percentage of net sales decreased to 74.9% for 2025, as compared to 77.6% for 2024 largely due to increased costs related to supply chain challenges, including increased product costs and increased freight costs.

    For the years ended December 31, 2025 and 2024, overall selling and administrative expenses were $39.6 million and $41.7 million, respectively. The decrease of $2.1 million primarily includes a $1.6 million decrease in payroll related costs, $0.6 million decrease in warehouse costs, a $0.1 million decrease in travel and entertainment, a $0.1 million decrease in charitable contributions, a $0.1 million decrease in miscellaneous administrative expenses, which was offset by a $0.4 million increase in marketing costs.

    Operating loss was $0.4 million in 2025 as compared to an operating income of $1.4 million in 2024.

    For the year ended December 31, 2025, the Company recorded an income tax provision of $12.3 million. The provision primarily reflects (i) the recognition of valuation allowances in certain jurisdictions based on updated assessments of the realizability of deferred tax assets, driven by changes in the expected mix of earnings across jurisdictions, and (ii) the recording of a deferred tax liability related to outside basis differences in certain foreign subsidiaries

    The combined DTA allowance adjustment and DTL recorded resulted in an additional $11.5 million charge to deferred tax expense, bringing the total net deferred tax position from a net deferred tax asset of $1.8 million at December 31, 2024, to a net deferred tax liability of $9.7 million at December 31, 2025.

    Management notes that the DTL recorded as of December 31,2025, reflects the Company's current assessment of the provision under ASC 740-30 with respect to undistributed earnings of foreign subsidiaries and does not represent a current cash tax obligation. The Company continues to evaluate available planning strategies and structural options to mitigate the long-term impact of its tax structure, including those related to intercompany balances and applicable tax treaties across its international subsidiary network

    Primarily due to foreign exchange losses, other expense was $2.1 million for the year ended December 31, 2025. At December 31, 2024, other income was $2.6 million, primarily due to foreign exchange gains.

    Net loss for 2025 was $15.2 million, or $8.00 per diluted share, as compared to net income of $2.5 million, or $1.32 per diluted share, for 2024

    As of December 31, 2025, the Company's cash and cash equivalents decreased to $6.2 million from $11.4 million as of December 31, 2024.

    Landen Fredrick, President and CEO, acknowledged that "2025 was a challenging year for Mannatech, particularly in North America, where system-related issues affected our sales momentum. In the Asia/Pacific region, we also continued to face persistent economic challenges. However, we remain focused on implementing new revenue programs and incentives, operating as a lean organization, and carefully managing our expenses moving forward."

    Liquidity and Cash Flow

    For the fiscal year ended December 31, 2025, Mannatech generated net sales of $108.0 million against a backdrop of broader macroeconomic pressures affecting the global direct-selling industry. While net sales reflected a year-over-year decline of $9.9 million compared to 2024, the Company responded with meaningful operational discipline, reducing total operating expenses by $8.6 million.

    Gross profit of $81.0 million reflects a gross margin of 74.9%, demonstrating the continued strength and resilience of the Company's product economics. Operating loss from core business activities was $0.4 million, a near-breakeven result that underscores the effectiveness of cost management efforts relative to the revenue environment.

    The reported net loss of $15.2 million is predominantly attributable to income tax charges of $12.3 million, which includes a non-cash deferred income tax expense of $11.5 million. These charges represent non-cash accounting adjustments and do not reflect operating cash consumption. The Company's net operating cash outflow of $2.8 million reflects primarily the timing of working capital settlements; underlying cash consumption before working capital movements was less than $1.1 million for the year.

    During the year ended December 31, 2025, management made significant progress in reducing aged payables, strengthening vendor relationships and improving the overall quality of the balance sheet. Finance lease obligations were substantially reduced, with repayments declining from $1.6 million in 2024 to $0.3 million in 2025, reflecting a meaningfully lighter obligation profile.

    The Company ended the fiscal year with $7.0 million in cash and cash equivalents. Management remains focused on operational efficiency, global market development, and prudent capital stewardship as the Company navigates the current business environment.

    Management's Statement

    The Company experienced an increase in costs during the period, driven by a combination of factors including rising tariffs, global supply chain pressures, and the broader geopolitical climate. Evolving trade policies and the imposition of new or expanded tariffs have contributed to higher input costs, increased logistics expenses, and greater supplier pricing volatility. These dynamics, amplified by ongoing geopolitical uncertainties, have placed incremental pressure on our cost structure and margins. The Company continues to monitor these developments closely and is actively pursuing mitigation strategies, including supplier diversification, pricing adjustments, and operational efficiencies. However, our ability to fully offset these impacts may be constrained by operational capacity, supplier limitations, and continued market volatility, particularly in the near term. Should geopolitical tensions and trade policy conditions persist or deteriorate further, there could be a continued adverse effect on our costs, margins, and overall financial performance.

    Non-GAAP Financial Measures

    In addition to results presented in accordance with GAAP, this press release and related tables include certain non-GAAP financial measures, including a presentation of Constant dollar measures. The Company discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations.

    The Company believes that these non-GAAP financial measures provide useful information to investors because they are an indicator of the strength and performance of ongoing business operations. The constant currency figures are financial measures used by management to provide investors with an additional perspective on trends. Although management believes the non-GAAP financial measures enhance investors' understanding of their business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. Please see the accompanying table entitled "Non-GAAP Financial Measures" for a reconciliation of these non-GAAP financial measures.

    Safe Harbor statement

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "may," "will," "should," "hope," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "approximates," "predicts," "projects," "potential," and "continues" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

    ^ Mannatech operates in China under a cross-border e-commerce platform that is separate from its network marketing model.

    Individuals interested in Mannatech's products or in exploring its business opportunity can learn more at Mannatech.com.

    Contact Information:

    Erin K. Barta

    General Counsel and Corporate Secretary

    214-724-3378

    [email protected]

    www.mannatech.com

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS 

    (in thousands, except share and per share information)
     
      December 31,

    2025
      December 31,

    2024
     
    ASSETS        
    Cash and cash equivalents $6,185  $11,396 
    Restricted cash  550   550 
    Accounts receivable, net of allowance for credit losses of $756 and $935 as of December 31,

    2025 and 2024, respectively
      1   19 
    Income tax receivable  736   737 
    Inventories, net  10,123   10,405 
    Prepaid expenses and other current assets  1,701   1,755 
    Deferred commissions  1,280   1,259 
    Total current assets  20,576   26,121 
    Property and equipment, net  3,140   2,858 
    Operating lease right-of-use assets  3,292   2,094 
    Other assets  2,751   2,644 
    Deferred tax assets, net  —   1,770 
    Long-term restricted cash  234   569 
    Total assets $29,993  $36,056 
    LIABILITIES AND SHAREHOLDERS' EQUITY        
    Commissions and incentives payable $7,118  $8,642 
    Accrued expenses  3,128   3,832 
    Deferred revenue  3,086   3,027 
    Accounts payable  2,410   2,070 
    Current portion of operating lease liabilities  1,671   1,178 
    Taxes payable  1,029   1,788 
    Current notes payable  —   84 
    Current portion of finance lease liabilities  293   275 
    Total current liabilities  18,735   20,896 
    Long-term notes payable, excluding current portion  2,750   2,900 
    Operating lease liabilities, excluding current portion  2,253   1,576 
    Other long-term liabilities  1,340   1,390 
    Finance lease liabilities, excluding current portion  388   680 
    Deferred tax liabilities, net  9,750   — 
    Total liabilities  35,216   27,442 
    Commitments and contingencies (Note 13)        
    Shareholders' equity:        
    Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding  —   — 
    Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and

    1,900,930 shares outstanding as of December 31, 2025 and 2,742,857 shares issued and

    1,884,814 shares outstanding as of December 31, 2024
      —   — 
    Additional paid-in capital  33,032   33,027 
    Retained earnings (accumulated deficit)  (14,024)  1,189 
    Accumulated other comprehensive loss  (4,669)  (5,666)
    Treasury stock, at average cost, 841,927 shares as of December 31, 2025 and 858,043 shares

    as of December 31, 2024
      (19,562)  (19,936)
    Total shareholders' equity  (5,223)  8,614 
    Total liabilities and shareholders' equity $29,993  $36,056 





    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share information)
     
      For the three months ended  For the years ended 
      December 31,  December 31, 
      2025  2024  2025  2024 
    Net sales $26,635  $29,007  $108,038  $117,866 
    Cost of sales  6,584   5,643   27,079   26,406 
    Gross profit  20,051   23,364   80,959   91,460 
    Operating expenses:                
    Commissions and incentives  10,415   12,072   41,727   48,309 
    Selling and administrative expenses  9,793   10,428   39,658   41,722 
    Total operating expenses  20,208   22,500   81,385   90,031 
    (Loss) income from operations  (157)  864   (426)  1,429 
    Interest expense, net  (127)  (83)  (406)  (279)
    Other income (expense), net  494   2,095   (2,057)  2,590 
    Income (loss) before income taxes  210   2,876   (2,889)  3,740 
    Income tax provision  (11,505)  (614)  (12,324)  (1,250)
    Net income (loss) $(11,295) $2,262  $(15,213) $2,490 
    Income (loss) per common share:                
    Basic $(5.94) $1.20  $(8.00) $1.32 
    Diluted $(5.94) $1.20  $(8.00) $1.32 
    Weighted-average common shares outstanding:                
    Basic  1,901   1,885   1,901   1,885 
    Diluted  1,901   1,885   1,901   1,885 



    Net sales by region for the fiscal year 2025 and 2024 were as follows (in millions, except percentages):

      December 31, 
    Region 2025  2024 
    Americas $32.5   30.1% $39.7   33.7%
    Asia/Pacific  66.4   61.5%  69.0   58.5%
    EMEA  9.1   8.4%  9.2   7.8%
    Total net sales $108.0   100.0% $117.9   100.0%



    Non-GAAP Financial Measures (Sales, Gross Profit and Income from Operations in Constant Dollars)

    To supplement its financial results presented in accordance with generally accepted accounting principles in the United States ("GAAP"), Mannatech discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations. It refers to these adjusted financial measures as Constant dollar items, which are non-GAAP financial measures. The Company believes these measures provide investors with an additional perspective on trends. To exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, it calculates current year results and prior year results at a constant exchange rate, which is the prior year's rate. Currency impact is determined as the difference between the actual GAAP results and the recalculated results for the current year at the Constant dollar rates.

    The tables below reconcile fiscal year 2025 and 2024 Constant dollar net sales, gross profit and income from operations to GAAP net sales, gross profit and income from operations. (in millions, except percentages):

    Year ended 2025  2024  Constant $ Change 
      GAAP      Non-GAAP  GAAP         
      Measure:  Translation  Measure:  Measure:         
      Total $  Adjustment  Constant $  Total $  Dollar  Percent 
    Net sales $108.0  $1.9  $109.9  $117.9  $(8.0)  (6.8)%
    Gross profit $81.0  $1.4  $82.4  $91.5  $(9.1)  (9.9)%
    Loss from operations $(0.4) $0.5  $0.1  $1.4  $(1.3)  (93.0)%





    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)
     
      For the years ended December 31,
       2025   2024 
    CASH FLOWS FROM OPERATING ACTIVITIES:    
    Net (loss) income $(15,213) $2,490 
    Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:    
    Depreciation and amortization  1,092   1,534 
    Non-cash operating lease expense  1,572   1,541 
    Provision for inventory losses  120   777 
    Reversal of allowance for credit losses  (128)  (312)
    Loss on disposal of assets  —   2 
    Gain on disposal of subsidiary  —   (228)
    Unrealized loss (gain) from foreign exchange  1,563   (3,257)
    Stock-based compensation expense  379   291 
    Deferred income taxes  11,520   (159)
    Changes in operating assets and liabilities:    
    Accounts receivable  173   344 
    Income tax receivable  4   (277)
    Inventories  313   2,474 
    Prepaid expenses and other current assets  835   2,094 
    Deferred commissions  (19)  859 
    Other assets  (226)  625 
    Accounts payable  315   (1,857)
    Accrued expenses and other long-term liabilities  (2,912)  (4,289)
    Taxes payable  (781)  451 
    Commissions and incentives payable  (1,628)  887 
    Deferred revenue  58   (1,729)
    Net cash (used in) provided by operating activities  (2,963)  2,261 
    CASH FLOWS FROM INVESTING ACTIVITIES:    
    Acquisition of property and equipment  (1,353)  (297)
    Proceeds from sale of assets  —   12 
    Net cash used in investing activities  (1,353)  (285)
    CASH FLOWS FROM FINANCING ACTIVITIES:    
    Proceeds from notes payable  —   3,600 
    Repayment of note payable  (234)  — 
    Repayment of finance lease obligations and other financing obligations  (327)  (1,639)
    Net cash (used in) provided by financing activities  (561)  1,961 
    Effect of currency exchange rate changes on cash and cash equivalents and restricted cash  (669)  (809)
    (Decrease) increase in cash and cash equivalents and restricted cash  (5,546)  3,128 
    Cash and cash equivalents and restricted cash at the beginning of the year  12,515   9,387 
    Cash and cash equivalents and restricted cash at the end of the year $6,969  $12,515 





    Primary Logo

    Get the next $MTEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jobe Larry A was granted 4,790 shares, increasing direct ownership by 8% to 62,197 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    1/6/26 2:37:56 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Robbins Kevin Andrew was granted 4,790 shares, increasing direct ownership by 22% to 26,233 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    1/6/26 2:36:47 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Director John Seifrick A was granted 4,790 shares, increasing direct ownership by 53% to 13,746 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    1/6/26 2:35:41 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    9/10/24 5:45:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mannatech Reports Financial Results for Fourth Quarter and Year Ended 2025

    FLOWER MOUND, Texas, April 17, 2026 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter and year ended 2025. Fourth Quarter Results Fourth quarter net sales for 2025 were $26.6 million, a decrease of $2.4 million, or 8.2%, as compared to $29.0 million in the fourth quarter of 2024. During the fourth quarter, the Company's net sales declined 7.6% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.2 million in net sales as

    4/17/26 5:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Notification of Late Filing

    FLOWER MOUND, Texas, April 01, 2026 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ:MTEX), ("Mannatech" or "the Company") announced today that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission with regard to its annual report on Form 10-K (the "2025 Form 10-K") for the fiscal year ended December 31, 2025. Form 12b-25 allows the Company an automatic extension of 15 additional calendar days to file the 2025 Form 10-K, which is due on March 31, 2026. The Company expects to file the 2025 Form 10-K as soon as practicable by April 15, 2026, in accordance with Rule 12b-25. The 12b-25 filing is available on the Company's website under ir

    4/1/26 6:47:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Third Quarter 2025

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. Th

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    SEC Filings

    View All

    Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MANNATECH INC (0001056358) (Filer)

    4/15/26 5:14:32 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Mannatech Incorporated

    10-K - MANNATECH INC (0001056358) (Filer)

    4/15/26 5:08:37 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form NT 10-K/A filed by Mannatech Incorporated

    NT 10-K/A - MANNATECH INC (0001056358) (Filer)

    4/2/26 3:41:56 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    View All

    Mannatech Announces Results of Annual Shareholders' Meeting

    Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

    6/5/25 2:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

    Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

    11/26/24 4:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

    Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

    7/1/24 5:46:00 PM ET
    $AEZS
    $MTEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $MTEX
    Financials

    Live finance-specific insights

    View All

    Mannatech Reports Financial Results for Fourth Quarter and Year Ended 2025

    FLOWER MOUND, Texas, April 17, 2026 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter and year ended 2025. Fourth Quarter Results Fourth quarter net sales for 2025 were $26.6 million, a decrease of $2.4 million, or 8.2%, as compared to $29.0 million in the fourth quarter of 2024. During the fourth quarter, the Company's net sales declined 7.6% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.2 million in net sales as

    4/17/26 5:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Third Quarter 2025

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. Th

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Mannatech Incorporated

    SC 13G - MANNATECH INC (0001056358) (Subject)

    11/1/24 11:44:29 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    1/13/23 11:03:46 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    2/7/22 6:32:28 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care